Findings

What do systematic reviews say?

461 questions · 472 findings · 42 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 93 · 19.7%GRADE not reported 81 · 17.2%Very low 99 · 21%Low 103 · 21.8%Moderate 75 · 15.9%High 21 · 4.4%

Intravenous thyrotropin releasing hormone vs placebo

Adverse events related to treatment · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Very low

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in disability score · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Muscle strength · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Low

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Acquiring the ability to stand or walk · non‐ambulatory children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in quality of life · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in pulmonary function · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Adverse events related to treatment · non‐ambulatory children with SMA types II and III

Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 1.32 [0.92, 1.89]
1 study · 61 participants
Moderate

Oral valproic acid vs placebo

Change in disability score · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
31 participants
Low

Oral creatine vs placebo

Adverse events related to treatment · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Oral valproic acid vs placebo

Muscle strength · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
30 participants
Low

Oral valproic acid vs placebo

Acquiring the ability to stand or walk · ambulatory adults with SMA type III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral valproic acid vs placebo

Change in quality of life · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
28 participants
Moderate

Oral valproic acid vs placebo

Change in pulmonary function · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
24 participants
Low

Oral valproic acid vs placebo

Time from beginning of treatment until death or full‐time ventilation · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
33 participants
Low

Oral valproic acid vs placebo

Adverse events related to treatment · ambulatory adults with SMA type III

Oral valproic acid showed no clear difference in adverse events related to treatment compared with placebo (low certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 0.8 [0.44, 1.44]
33 participants
Low

Oral gabapentin vs placebo

Change in disability score · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Low

Oral gabapentin vs placebo

Muscle strength · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low

Interferon beta‐1a vs placebo

Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low

Brain‐derived neurotrophic factor vs placebo

Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low